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Abstract 
ME/CFS is a debilitating condition hardly discussed 
in the Maltese Islands, and was only recognized in 2009 
as a neurological disease in our archipelago despite it 
being recognized by WHO in 1969. The authors discuss 
the origin of the combined terminology ME/CFS, the 
importance of recognizing the condition at an early 
stage, the appropriate treatment and the potential role of 
the health services. The authors also highlight the lack of 
official statistical data available in the Maltese 
archipelago. 
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Introduction 
ME/CFS is a debilitating, chronic, acquired disease 
characterized by a range of disturbances effecting all 
body systems, but predominantly the neurological, 
endocrine and immune systems. Following normal 
physical or mental activity, ME/CFS sufferers 
experience profound fatigue, exhaustion, loss of muscle 
power, pain, joint tenderness and cognitive dysfunction. 
 
 
There are various case definitions used to describe 
chronically fatigued patients, however the most widely 
used is the 1994 Internal Classification of Disease 
definition of ME/CFS which includes three major 
requirements, and all must be met: 
 The presence of unexplained chronic fatigue which 
is clinically evaluated and has been persistent or 
relapsing for six months or more.  
 Functional impairment that significantly affects 
daily activities of work. 
  The presence of at least 4 of 8 case defining 
symptoms.  
 
 
 
 
 
Other conditions should be excluded such as sleep 
apnea, anemia, unresolved infections such as hepatitis B 
or C, side effects of medications and other major 
depressive disorders. (ICD-9-CM, 2011). 
 
The Terminology Crisis 
Since 1969, ME/CFS has been classified as a 
neurological disorder in the World Health Organisation 
(WHO) International Classification of Diseases (ICD 10 
G93.3).   
The combined terminology: ME/CFS has in-depth 
history and is still a grey area as many doctors are 
unsure which terminology to use. 
However, in October 2011, Carruthers rejected the term 
CFS and stated that: 5  
‘In view of more recent research and clinical experience 
that strongly point to widespread inflammation and 
multisystemic neuropathology, it is more appropriate 
and correct to use the term ‘myalgic encephalomyelitis’ 
(ME) because it indicates an underlying 
pathophysiology. It is also consistent with the 
neurological classification of ME in the World Health 
Organization’s International Classification of Diseases 
(ICD G93.3).’   
Despite this, many practitioners opt to make do 
with the combined terminology, to prevent 
misunderstandings within the medical, research and 
patient community, avoiding confusion within medical 
health care.  
 
Epidemiology 
Carruthers reported that the prevalence ranges from 
0.4% to 2.5% worldwide, around 235-700 per 100,000 
individuals, more prevalent than AIDS, lung or breast 
cancer. 2 
There is no current epidemiological data for the 
local Maltese Islands, despite the 800 sufferers living in 
the archipelago according to a local newspaper 
published in 2009. This was found to be confirmed by 
Dr. John Greensmith, representing ‘ME Free For All’ 
U.K based organization who obtained this calculation 
through foreign statistics in 2009.  
Until 2011, Malta did not recognize ME/CFS as a 
disability despite the syndrome enlisted as a 
neurological disorder by WHO.10 
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The Aetiology of ME/CFS and the relevant risk 
factors 
The aetiological causes of ME/CFS are topics of 
vigorous research and debate due to the multi-factorial 
pathogenesis (Figure 1). The scientific community has 
not yet identified the cause but suggest a variety of 
factors which can be classified into two: 
a. Predisposing factors  
b. Events that stress the immune system and prompt 
onset 
 
A. Predisposing factors 
According to Shepherd genetics, gender, age and 
psychological factors are the crucial predisposing 
factors. 20 The psychological factors are mainly 
excessive stress, a study carried out by Bentall indicate 
the presence of a stressful event experienced by one-
third of the patients prior to the onset of disease.37 The 
study conducted by Bell has shown that women are 
more vulnerable to ME/CFS and three-fourths of the 
sufferers develop the condition in the mid-40 age 
group.10 
 
B. Events that stress the immune system and 
prompt onset 
ME/CFS frequently follows an acute infection such 
as an upper respiratory infection, amongst others. 
However, there is no conclusive evidence for the latter 
with no specific pathogen.  Carruthers  argues that the 
following are thought to related:2 
 Epstein-Barr Virus  
 Human Herpesvirus-6 and 7 
 Enterovirus  
 Cytomegalovirus  
 Lentivirus 
 Chlamydia  
 Mycoplasma  
 
Clinical Features 
Physical and emotional fatigue is the main clinical 
symptom, which lasts for more than 24 hours and is not 
treated with sleep. This causes loss of concentration, 
short term memory loss and muscle pain.  Headaches 
and sore throats are frequent accompanying symptoms 
and usually persist for 6 months or more (Figure 1). 
 
Investigations 
There is no single diagnostic test for ME/CFS , and 
testing is done to exclude other organic causes for the 
clinical features.  Blood test may include checking the 
levels of creatinine kinase to exclude a myopathy.  This 
may further be supported with an electromyogram.  EEG 
studies have revealed particular characteristics pertinent 
to ME/CFS in children even though such evidence has 
yet to be further evaluated.29 
 
Treatment 
‘In my experience, CFS is one of the most disabling 
diseases that I care for, far exceeding HIV disease 
except for the terminal stages.’ 15 
Muscle symptoms are common in ME/CFS 
patients, prompting research regarding the disturbance 
of carnitine homeostasis. According to Evans et al. this 
may possibly be due to a decreased carnitine 
palmitoyltransferase-I (CPT-I) activity and accumulation 
of omega-6 fatty acids.30 Hence, possibly an increase 
intake of omega-3 fatty acids and L-carnitine will 
increase CPT-I activity, improving symptoms. 
Perrin et al. suggests that ‘Perrin Technique’, an 
osteopathic intervention may be the key to future 
treatment whereby findings suggest that many of the 
symptoms experienced by ME/CFS patients are due to a 
lymphatic drainage disturbance.29 The ‘Perrin 
Technique’ stimulates toxin drainage out of lymphatic 
system into the blood, which are then detoxified by the 
liver (Figure 2). This results in a decrease toxin level 
within the cerebrospinal fluid and hence improved 
symptoms. 
Holtorf reported that ME/CFS patients have a 
reduced cortisol output and hypothalamic-pituitary-
adrenal axis hypofunction which causes the fatigue. 15 
Cortisol treatment should be part of the multi-system 
treatment program for ME/CFS individuals. 
Further research is required to locate the site of 
abnormality in brainstem perfusion which Costa et al. 
reported a decrease in ME/CFS patients.3 This may 
explain why patients experience cognitive dysfunction, 
the typical ‘brain fog’.  
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Figure 1: Summary of factors contributing to ME/CFS and the clinical features of the condition. 
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Figure 2: The ‘Perrin Technique’. A therapy recommended by Perrin et al. which causes toxin drainage from the 
lymphatic system.35 
 
 
 
 
 
 
 
 
 
 
 
The Role of Health Services 
In Malta, issues relating to ME/CFS are hardly 
discussed, with very few individuals within the 
community aware about the condition.  
To date there is no specific treatment for ME/CFS apart 
from pharmacological therapy to alleviate symptoms. 
However, a CFS/ME Multidisciplinary team should be 
set up and available to all individuals suffering from the 
disorder on the island, rather than patients seeking 
treatment regimens internationally.  
This group will increase the awareness of CMS/ME 
and develop group and individualized therapeutic 
options for sufferers by: 
 Offering a rehabilitation program which advices 
patients on energy and anxiety management.  
 Advising patients how to overcome psychological 
obstacles, how to maintain a well balanced diet 
despite their numerous sensitivities 
 
 Setting up a lifestyle management program 
designed by occupational therapists, which advices 
patients on work simplification techniques. 
 Adequate pharmacological treatments to alleviate 
the numerous symptoms patients experience. 
 Providing professional Adaptive Pacing Therapy 
(APT), Graded exercise therapy programs (GET) 
and Cognition Behaviour therapy (CBT). 
According to McCrone et al. the PACE trial 
compared the four main treatments: general advice about 
management, APT, CBT and GET available for 
ME/CFS patients, and found CBT as the most cost-
effective from a health care perspective.8 
The lack of CFS/ME services will pose a problem to 
individuals who suffer from this disorder who without 
appropriate local services, will increase the incidence of 
the disease within the Maltese islands. 
Thus, with adequate awareness, knowledge and 
health services, ME/CFS individuals may become 
productive citizens within the community. This will 
benefit themselves and society. 
 
Conclusion 
ME/CFS is a disorder characterized by numerous 
systemic symptoms which severely impacts the quality 
of life, equivalent to late stage AIDS. 19 A few patients 
recover whilst others are left permanently debilitated.32 
Although CBT was found to be the most cost-effect 
therapy for ME/CFS, there is no specific cure and hence 
is a disorder which is being thoroughly researched. 
Regarding the local status in the Maltese islands, a 
multi-disciplinary team should be developed, for 
adequate treatment and management. More educational 
awareness within the medical community should be 
provided as this prevents late and incorrect diagnoses. 
This will prevent any possible sources of error in future 
epidemiological studies. 
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